460
Participants
Start Date
June 9, 2015
Primary Completion Date
July 17, 2018
Study Completion Date
July 17, 2018
Anifrolumab
Anifrolumab IV administration every 4 weeks from Week 0 to Week 48 for a total of 13 doses
Placebo
Placebo IV administration every 4 weeks from Week 0 to Week 48
Research Site, Barranquilla
Research Site, Arequipa
Research Site, Taichung
Research Site, Budapest
Research Site, St Leonards
Research Site, Kogarah
Research Site, Fitzroy
Research Site, Hamilton
Research Site, Debrecen
Research Site, Wellington
Research Site, Szeged
Research Site, Zalaegerszeg
Research Site, Taipei
Research Site, Berlin
Research Site, Great Neck
Research Site, New Hyde Park
Research Site, Lima
Research Site, Lima
Research Site, Lima
Research Site, Lima
Research Site, Pittsburgh
Research Site, Philadelphia
Research Site, Wyomissing
Research Site, Milan
Research Site, Milan
Research Site, Vinnytsia
Research Site, Hagerstown
Research Site, Hagerstown
Research Site, Raleigh
Research Site, Charlotte
Research Site, Charlotte
Research Site, Charleston
Research Site, Charleston
Research Site, Charleston
Research Site, Decatur
Research Site, Lawrenceville
Research Site, Marietta
Research Site, Haifa
Research Site, Ormond Beach
Research Site, Orlando
Research Site, Orlando
Research Site, Vero Beach
Research Site, Miami
Research Site, Aventura
Research Site, Plantation
Research Site, Tampa
Research Site, Padua
Research Site, Birmingham
Research Site, Göttingen
Research Site, Memphis
Research Site, Jackson
Research Site, Taichung
Research Site, Cleveland
Research Site, Middleburg Heights
Research Site, Ternopil
Research Site, Petah Tikva
Research Site, Kfar Saba
Research Site, Grand Rapids
Research Site, Cologne
Research Site, Glendale
Research Site, Jeonju
Research Site, Frankfurt am Main
Research Site, Gwangju
Research Site, Suwon
Research Site, Tel Aviv
Research Site, Zaporizhzhia
Research Site, Baton Rouge
Research Site, Oklahoma City
Research Site, Kirchheim
Research Site, Tulsa
Research Site, Mesquite
Research Site, Dallas
Research Site, Houston
Research Site, Houston
Research Site, San Antonio
Research Site, Austin
Research Site, Austin
Research Site, Lviv
Research Site, Lviv
Research Site, Amarillo
Research Site, Aurora
Research Site, Kaohsiung Hsien
Research Site, Idaho Falls
Research Site, Boise
Research Site, Uzhhorod
Research Site, Los Alamitos
Research Site, Thousand Oaks
Research Site, Bogotá
Research Site, Bogotá
Research Site, Cluj-Napoca
Research Site, Brasov
Research Site, Tg Mures
Research Site, Armenia
Research Site, Bucaramanga
Research Site, Galati
Research Site, Viña del Mar
Research Site, Haifa
Research Site, Osorno
Research Site, Santiago
Research Site, Jerusalem
Research Site, El Cajon
Research Site, La Jolla
Research Site, Minneapolis
Research Site, Nashua
Research Site, Freehold
Research Site, Córdoba
Research Site, San Miguel de Tucumán
Research Site, Belo Horizonte
Research Site, Juiz de Fora
Research Site, Porto Alegre
Research Site, Salvador
Research Site, Medellín
Research Site, Dessau-RoBlau
Research Site, Lima
Research Site, Lima
Research Site, Bialystok
Research Site, Bydgoszcz
Research Site, Elblag
Research Site, Krakow
Research Site, Lublin
Research Site, Nadarzyn
Research Site, Poznan
Research Site, Poznan
Research Site, Sosnowiec
Research Site, Starachowice
Research Site, Szczecin
Research Site, Ustroń
Research Site, Warsaw
Research Site, Warsaw
Research Site, Bucharest
Research Site, Bucharest
Research Site, Bucharest
Research Site, Daejeon
Research Site, Seoul
Research Site, Seoul
Research Site, Kiev
Research Site, Kyiv
Research Site, Kyiv
Research Site, Brighton
Research Site, Doncaster
Research Site, Leeds
Research Site, London
Research Site, Manchester
Research Site, Romford
Research Site, Staffordshire
Lead Sponsor
Collaborators (1)
PRA Health Sciences
INDUSTRY
AstraZeneca
INDUSTRY